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Abstract
Background: Osteosarcoma is the most prevalent primary bone malignancy in children and young adults. These
tumors are highly metastatic, leading to poor outcome. We previously demonstrated that Cysteine-rich protein 61
(CYR61/CCN1) expression level is correlated to osteosarcoma aggressiveness in preclinical model and in patient
tumor samples. The aim of the present study was to investigate the CYR61-induced intracellular mechanisms
leading to the acquisition of an invasive phenotype by osteosarcoma cells.
Methods: Modified murine and human osteosarcoma cell lines were evaluated for cell adhesion, aggregation
(spheroid), motility (wound healing assay), phenotypic markers expression (RT-qPCR, western blot). Cell-derived
xenograft FFPE samples and patients samples (TMA) were assessed by IHC.
Results: CYR61 levels controlled the expression of markers related to an Epithelial-mesenchymal transition (EMT)-like
process, allowing tumor cells to migrate acquiring a competent morphology, and to be able to invade the surrounding
stroma. This phenotypic shift indeed correlated with tumor grade and aggressiveness in patient samples and with the
metastatic dissemination potential in cell-derived xenograft models. Unlike EGFR or PDGFR, IGF1Rβ levels correlated
with CYR61 and N-cadherin levels, and with the aggressiveness of osteosarcoma and overall survival. The expression
levels of IGF1Rβ/IGF1 axis were controlled by CYR61, and anti-IGF1 neutralizing antibody prevented the CYR61-induced
phenotypic shift, aggregation, and motility abilities.
Conclusions: Taken together, our study provides new evidence that CYR61 acts as a key inducing factor in the
metastatic progression of osteosarcoma by playing a critical role in primary tumor dissemination, with a process
associated with IGF1/IGFR stimulation. This suggests that CYR61 may represent a potential pivotal target for therapeutic
management of metastases spreading in osteosarcoma, in correlation with IGF1/IGFR pathway.
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Background
Osteosarcoma is the most common primary malignant
non-hematopoietic bone tumor, particularly affecting ado-
lescents and young adults. These tumors frequently spread
locally or to distant organs (predominately to the lungs,
brain or other skeletal sites). Patients with localized osteo-
sarcoma are treated by surgery, with neo-adjuvant and
adjuvant chemotherapy, and have an event-free-survival
(EFS) of 60–70% at 5 years. In contrast, patients with
detectable metastases at diagnosis or with recurrent
disease show a dismal overall prognosis with 5-year EFS of
less than 30% [1]. This major clinical problem precludes
the development of new therapeutic strategies able to
improve these poor current clinical outcomes.
The immediate-early gene CYR61 encodes a member
of the extracellular matrix-associated CCN family of six
homologous cysteine-rich proteins comprising connect-
ive tissue growth factor (CTGF), nephroblastoma over-
expressed (NOV), and Wnt-induced secreted proteins
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(WISPs). CYR61 is involved in multiple physiological
functions among which skeletal and cardiovascular
development and injury repair [2–5]. In different solid
tumors, CYR61 was shown to promote tumor growth
and vascularization as well as cell invasiveness and
metastasis [6–10]. We previously highlighted a positive
correlation between CYR61 protein level and osteosar-
coma cell dissemination both in vitro and in vivo [11, 12].
CYR61 was able to promote tumor neo-angiogenesis and
extracellular matrix remodeling suggesting a potential role
in tumor cells dissemination [11, 12]. These in vitro and
preclinical observations have been strengthened at a clin-
ical level since CYR61 protein levels were associated with
tumor grade in osteosarcoma patients [11, 12]. Thus,
metastatic tumor samples express higher levels of CYR61
than localized tumors, and that recurrent tumor tissues
exhibit the highest levels of CYR61. Moreover, CYR61
protein levels in osteosarcoma biopsies correlate signifi-
cantly with poor overall survival of the patients [13]. As a
consequence CYR61 may be associated with a metastatic-
promoting activity in osteosarcoma. Yet the precise mech-
anism of action of CYR61 on osteosarcoma cell dissemin-
ation ability remains unclear.
A developmental cellular program called Epithelial-to-
Mesenchymal Transition (EMT) confers epithelial cancer
cells with novel functions including migration, invasion to
the surrounding stroma and dissemination to secondary
sites, substantiating the progression of early-stage tumor to-
wards a high-grade malignancy [14, 15]. This EMT pro-
gram comprises the activation of transcription factors
(Slug, Snail, Twist, ZEB1…) driving the downregulation or
loss of epithelial cell junction markers (E-cadherin…) and
the upregulation or gain of mesenchymal markers (N-cad-
herin, Vimentin…). Many extracellular signals can activate
a trans-differentiation program in epithelial cells that leads
to EMT [16]. In this context, growth factors such as Hep-
atocyte Growth Factor (HGF), Fibroblast Growth Factor
(FGF), Epidermal Growth Factor (EGF), Platelet-Derived
Growth Factor (PDGF), Insulin-like Growth Factor 1
(IGF1) Transforming Growth Factor-β (TGFβ) or Bone
Morphogenetic Proteins (BMPs), often induce EMT in
epithelial cells through the activation of transmembrane
tyrosine kinase receptors (RTKs) [14].
In the resting phase a single layer of osteoblasts cover
all bone surfaces creating a histological structure reminis-
cent of an epithelial-like monolayer. In contrast, trans-
formed cells of osteosarcoma, despite their mesenchymal
origin, have recently been reported to undergo a pheno-
typic switch evocative of an EMT-like process, with the
acquisition of an increase invasiveness and motility lead-
ing to increased pro-metastatic activity. This event shares
several features of the classical EMT observed in solid
tumors of an epithelial origin [17–20]. The tumor micro-
environment consisting in surrounding stroma plays a key
role in osteosarcoma tumorigenesis. Tumor cells are
embedded in an intricated network of fibrillar extracellular
matrix with contain a rich mixture of growth factors
within the bone marrow stroma. TGFβ is the only one
reported up to now to promote osteosarcoma invasion
and metastasis through the induction of an EMT-like
process [21].
The present study reports that CYR61 triggers specific
and characteristic features relative to EMT in vitro, in a
murine preclinical model and in patient tumor samples.
We also report a positive correlation between CYR61
and IGF1Rβ levels and show that CYR61 controls IGF1
and IGF1Rβ expression levels, modulating the related
intracellular signaling. Taken together, our data demon-
strate the involvement of CYR61 in the early metastatic
cascade such as the acquisition of invasive properties by
osteosarcoma cells. This reinforces CYR61 as a pivotal
factor for the therapeutic management of metastasis in
osteosarcoma.
Results
CYR61 and N-cadherin expression levels are correlated in
osteosarcoma
Tissue microarray (TMA) comprised of 233 osteosarcoma
and 28 normal bone core samples (Additional file 1: Figure
S1) was used to assess the expression level of CYR61 and
N-cadherin (Fig. 1a). The average IHC staining score for
N-cadherin and CYR61 increased with tumor aggressive-
ness: metastatic and recurrent tumor tissues expressed
respectively 1.6 and 2 times more N-cadherin or CYR61
than localized primary tumor tissues (Fig. 1b-c). Further-
more, the expression levels of these two markers were posi-
tively correlated (Pearson correlation coefficient = 0.523; p
= 7 × 10− 4; Fig. 1d). CYR61 expression was associated with
significant decrease in overall survival compared to low ex-
pression (p = 0.0162; Fig. 1e). A Cox proportional-hazards
regression model confirmed that CYR61 up-regulation
predicted higher risk of death (p = 0.041).
Altogether, these data indicate close correlation between
CYR61 and N-cadherin expression level and tumor
aggressiveness in osteosarcoma samples.
CYR61 controls the relative level of N- and E-cadherin in
osteosarcoma cells
In order to determine the influence of CYR61 on osteosar-
coma cell behavior, new osteosarcoma stable cell lines
were generated by lentiviral transduction to silence or
overexpress CYR61 (Fig. 4b). Modified and parental cells
injected to mice generated primary tumors that expressed
various CYR61 levels, as assessed by IHC (Fig. 2a-b).
CYR61 silencing led to a reduced expression of
N-cadherin (− 34%, p = 3 × 10− 6, Fig. 2c-d), and an in-
creased expression of E-cadherin compared to control
tumor cells (+ 58%, p = 2 × 10− 13; Fig. 2e-f). Conversely,
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CYR61 overexpression led to an increased expression of
N-cadherin (+ 41%, p = 1.3 × 10− 4), and a slightly reduced
expression of E-cadherin (− 9%, p = 0.057). Globally, the
N/E-cadherin ratio fully correlated to CYR61 expression
levels (Fig. 2g).
The lung metastatic burden was assessed by HES stain-
ing of paraffin-embedded sections (Fig. 3a). The number
and size of metastatic nodules positively correlated with
CYR61 and with N-cadherin/E-cadherin expression level
ratio (Fig. 3b-d).
Altogether, these data indicate that CYR61 controls
the relative levels of N- and E-cadherin in osteosarcoma
cells. Furthermore, the relative levels of N-, E-cadherin
and CYR61 correlate with tumor spread, suggesting the






Fig. 1 CYR61 controls the levels of N-cadherin in tumor tissues. (a) Immunohistochemical staining for N-cadherin and CYR61 of tissue microarray
(TMA) containing human samples derived from localized, metastatic or recurrent osteosarcoma. No primary antibody verifies the specificity of the
staining and lacked background noise. b, c Box plot of IHC staining score for CYR61 (b) and N cadherin (c). Results are expressed as arbitrary units
(A.U.) (d) Spearman correlation between N-cadherin and CYR61 expression levels in human samples (n = 47). The black line shows the
regression line. (e) Kaplan-Meier survival curves from patients with low CYR61 level or patients with highest CYR61 level.






Fig. 2 CYR61 controls the relative levels of N-and E-cadherin in tumor tissues. Immunohistochemical staining for CYR61 (a), N-cadherin (c), and E-cadherin
(e) of control, CYR61-silenced or CYR61-overexpressing cell-line derived xenografts. Box plot of IHC staining scores for CYR61 (b), N-cadherin (d), and E-
cadherin (f). a: p< 0.05 vs. control cells. g Spearman correlation between the number of metastases, and N−/E-cadherin ratio in murine samples
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CYR61 controls the relative expression level of epithelial
and mesenchymal markers
In order to better characterize the molecular mechanisms
involved in the pro-metastatic effect of CYR61, gene
expression levels of a panel of epithelial and mesenchymal
markers were assessed by real time RT-qPCR in both mur-
ine K7M2 and human U2OS modified cell lines (Fig. 4a).
As expected, CYR61 silencing led to a reduced expression
of N-cadherin and an increased expression of E-cadherin,
and vice versa CYR61-overexpression led to an increased
expression of N-cadherin and a reduced expression of
E-cadherin in both murine K7M2 and human U2OS
cell lines. CYR61 silencing was also associated with a
reduced expression of mesenchymal-related markers
(Snail-1, Snail-2/Slug, Twist1, Vimentin, ZEB1,
Mucin-1) and an increased expression of epithelial-
related markers (Occludin, Desmoplakin, Entactin,





Fig. 3 CYR61 controls the osteosarcoma metastatic potential in correlation with the relative levels of N- and E-cadherin. a H&E staining of lung
tissue sections isolated from mice injected with control, shCYR61, or OE-CYR61 cells. Spearman correlations between the metastatic nodules
number (b), area of metastases (c) or the relative metastatic pulmonary tissue volume (d) and N−/E-cadherin ratio
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Conversely, CYR61 overexpression led to an increase
in gene expression levels of mesenchymal related
markers and a decrease in epithelial-related markers.
Likewise, modulation of CYR61 expression levels was
associated with matrix metalloproteases-2, − 3, − 9,
and − 14 and TIMP2 in both K7M2 and U2OS cell
lines.
The protein expression level of N- and E-cadherin was
assessed by western blot (Fig. 4b). As expected, CYR61
silencing led to a reduced expression of N-cadherin and
an increased expression of E-cadherin. Conversely,
CYR61 overexpression led to an increased expression of
N-cadherin and a reduced expression of E-cadherin.
Globally, the N/E-cadherin ratio fully correlated to
A
B C
Fig. 4 CYR61 controls osteosarcoma cell phenotype in vitro. a Expression pattern of a panel of mesenchymal and epithelial markers in K7 M2 and
U2OS cell lines, as assessed by RT-qPCR. The relative mRNA levels were calculated using the 2–ΔΔCT method and expressed as Log2 of fold
change (mean ± standard deviation). a: p < 0.05 vs. control cells. b Expression pattern of CYR61, N- and E-cadherin proteins in K7 M2 and U2OS
cell lines, as assessed by Western blot. Actin was used as loading control. c Spearman correlation between N−/E-cadherin ratio and CYR61
expression level in K7 M2 and U2OS cell lines. The black line shows the regression line
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CYR61 expression level in murine K7M2 and human
U2OS cell lines (Fig. 4c).
Altogether, these data indicate that CYR61 modulates
the expression level of a variety of markers related to
epithelial-to-mesenchymal transition (EMT) in osteosar-
coma cells.
CYR61 controls the cell morphology and relative
adhesion performance
Control and CYR61-modified osteosarcoma cells, rou-
tinely cultured on plastic in serum-supplemented
medium, exhibited different morphological characteris-
tics (Additional file 2: Figure S2A). CYR61-silenced cells
exhibited a more cuboidal shape than control cells
whereas CYR61 over-expressing cells exhibited an elon-
gated and more or less branched shape. As a result, the
average maximum cell length was related to CYR61 ex-
pression level (Pearson correlation coefficient > 0.99, p <
0.05; Additional file 2: Figure S2B).
Furthermore, cells were tested in 3-D conditions for
spheroid formation. K7M2 cells, seeded in poly-Hema
coated 96-well round-bottomed plates, reproducibly
formed condensed and organized 3D structures in less
than 24 h (Additional file 2: Figure S2C-D). CYR61 silen-
cing lowered osteo-spheroid growth whereas CYR61
overexpression markedly increased osteo-spheroid
growth and cell invasion. The migration of cells out of
the spheroid into the close Matrigel was also clearly fa-
vored for cells overexpressing CYR61, and markedly re-
duced for CYR61-silenced cells. Using this 3D assay as a
more physiologically predictive cancer invasion model,
our results confirmed that CYR61 play a key role in
osteosarcoma cell invasiveness.
The osteosarcoma cells ability to interact with the
extracellular matrix was evaluated using plastic surface
coated or not with some key bone matrix components
(Additional file 2: Figure S2E). The cell adhesion rate
onto uncoated plastic or laminin- or fibronectin-coated
surfaces was not dependent on CYR61 level. In contrast,
cell adhesion onto type I collagen was accelerated in si-
lenced cells and slowed in CYR61-overexpressing cells.
Altogether, these modulations of cell fate also suggest
a CYR61-dependent balance between mesenchymal and
epithelial-like phenotypes. Subsequent adhesive proper-
ties, both at cell-cell and cell-matrix levels, are
dependent on CYR61 levels.
CYR61 expression level correlates with that of IGF1Rβ,
not EGFR or PDGFR
In order to determine the upstream molecule triggering
the CYR61-dependent signaling pathway leading to
EMT-like process, the protein expression level of recep-
tors with tyrosine kinase activity (RTKs) was assessed on
TMA by IHC. As previously reported [22], the average
IHC staining score for EGFR and PDGFR increased with
tumor aggressiveness (Additional file 3: Figure S3A-B).
However, neither EGFR nor PDGFRα expression levels
correlate with CYR61 protein level (Additional file 3:
Figure S3C-D). In addition, neither EGFR nor PDGFRα
expression levels correlate with N-cadherin protein
levels (Additional file 3: Figure S3E-F). The expression
level of IGF1Rβ was higher in metastatic (2.7-fold; p =
0.0217) and even higher in recurrent tumor tissues
(3.3-fold, p = 3 × 10− 4) than in localized primary tumor
tissues (Fig. 5a-b). A Cox proportional-hazards regression
model confirmed that IGF1Rβ up-regulation predicted
higher risk of death (nonlinear risk; p = 0.026). The
IGF1Rβ expression level positively correlates with CYR61
and N-cadherin protein level in tumor tissues (Fig. 5c-d).
The expression level of IGF1Rβ was assessed by IHC
in primary tumors generated by injection of
CYR61-modified and parental cells (Fig. 5e-f ). Tumors
derived from CYR61 silenced cells showed a reduced ex-
pression of IGF1Rβ as compared to control tumor cells
(− 49%, p = 3 × 10− 5). Conversely, tumors derived from
CYR61 overexpressing cells showed a slight increased
expression of IGF1Rβ (+ 20%, p = 0.0376).
Altogether, these results indicate that CYR61 expres-
sion level associates with IGF1Rβ but not with EGFR or
PDGFR expression in osteosarcoma.
CYR61 controls the expression level of IGF1Rβ
In order to characterize the relationship between CYR61
and IGF1Rβ in osteosarcoma cells, control and
CYR61-modified osteosarcoma cells were tested for
IGF1Rβ expression levels (Fig. 6a). CYR61 silencing led
to a reduced expression of IGF1Rβ in both murine K7
M2 and human U2OS cell lines, as assessed by western
blot. Conversely, CYR61 overexpression led to an
increased expression of IGF1Rβ. The activity of IGF1Rβ,
reflected by its phosphorylation levels was correlated to
the expression level of the receptor. The phosphoryl-
ation state of downstream effectors such as GSK3β was
correlated to IGF1Rβ activity and CYR61 levels (Fig. 6a).
Control and CYR61-modified osteosarcoma cells were
then tested for IGF1Rβ promoter activity using gene
reporter assay (Fig. 6c). CYR61 silencing led to a decrease
in relative luciferase activity (− 30 and − 40%, p < 0.05) com-
pared to control cells whereas CYR61 overexpression led to
a higher luciferase activity in both murine K7M2 and hu-
man U2OS models (1.8- and 2.6-fold, p < 0.05). The supple-
mentation of culture medium with recombinant CYR61
also increased relative luciferase activity in control murine
K7M2 and human U2OS cells (2.3-fold and + 90%, respect-
ively, p < 0.05), resulting in a relative luciferase activity com-
parable to the CYR61-overexpressing cells. Similarly,
supplementation with recombinant CYR61 increased rela-
tive luciferase activity in CYR61-silenced murine K7M2
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and human U2OS cells (1.4- and 2-fold, respectively, p <
0.05), resulting in a relative luciferase activity comparable to
the control cells.
Altogether, these results indicate that CYR61 increased
IGF1Rβ promoter activity, leading to increased IGF1Rβ
expression levels in osteosarcoma cells and tumor.
CYR61 controls the expression level of IGF1 in
osteosarcoma cells
Control and CYR61-modified osteosarcoma cells were
tested for IGF1 expression levels. CYR61 silencing led to
a reduced expression of IGF1 in both murine K7M2 and





Fig. 5 CYR61 controls the expression level of IGF1Rβ. a Immunohistochemical staining for IGF1Rβ in human samples derived from localized,
metastatic or recurrent osteosarcoma. b Box plot of IHC staining score for IGF1Rβ in human samples. a: p < 0.05 vs. localized tumor. c Spearman
correlation between IGF1Rβ expression levels and CYR61 expression levels in human samples. The black line shows the regression line. d
Spearman correlation between IGF1Rβ expression levels and N-cadherin expression levels in human samples. The black line shows the regression
line. e Immunohistochemical staining for IGF1Rβ in cell line-derived xenograft of control, CYR61 silenced or CYR61-overexpressing cells. f Box plot
of IHC staining score for IGF1Rβ in murine samples. a: p < 0.05 vs. control cells





Fig. 6 CYR61 controls the expression level of IGF1Rβ and IGF1. a Expression pattern of IGF1Rβ protein in K7M2 and U2OS cell lines, as assessed by
Western blot. Actin was used as loading control. b Expression pattern of IGF1 protein in K7M2 and U2OS cell lines, as assessed by ELISA. Results are
expressed as mean ± standard deviation. a: p < 0.05 vs. control cells. c Relative luciferase activity of IGF1Rβ promoter construct in K7M2 and U2OS cell
lines incubated in the presence or absence of recombinant CYR61. a: p < 0.05 vs. control cells; b: p < 0.05 vs. untreated. d Expression pattern of IGF1 in
K7M2 and U2OS cell lines, as assessed by RT-qPCR. The relative mRNA levels were calculated using the 2–ΔΔCT method and expressed as Log2 of fold
change (mean ± standard deviation). a: p < 0.05 vs. control cells. e Expression pattern of a panel of mesenchymal and epithelial markers in CYR61
overexpressing cell lines, incubated with/without neutralizing anit-IGF antibody, as assessed by RT-qPCR. The relative mRNA levels were calculated
using the 2–ΔΔCT method and expressed as Log2 of fold change (mean ± standard deviation). a: p < 0.05 vs. control cells
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(up to − 90%, p < 0.05; Fig. 6d). Conversely, CYR61
overexpression led to an increased expression of IGF1
(16- and 4.7-fold, respectively, p < 0.05). Those correlated
variations were confirmed at a protein level as assessed by
ELISA on conditioned media (Fig. 6b).
CYR61-overexpressing cells were incubated in the pres-
ence of neutralizing anti-IGF1 antibody for 24 h before
evaluation of mRNA levels of EMT markers (Fig. 6e). All
tested mesenchymal markers were down-regulated in the
presence of anti-IGF1 antibody, whereas all epithelial
markers were up-regulated.
These results indicate that CYR61 induced IGF1 synthe-
sis by osteosarcoma cells, cooperating to the acquisition of
a more pronounced mesenchymal phenotype. They also
suggest that the inductive effects of the overexpression of
CYR61 on EMT markers could be limited by anti-IGF1
neutralizing antibody.
CYR61 influences cell motility and cell-cell interaction
through the IGF1/IGF1Rβ pathway
In order to evaluate the involvement of IGF1/IGF1Rβ path-
way in the pro-metastatic effect of CYR61, cells were tested
for cell migration and aggregation under different culture
conditions. As expected, culture medium supplementation
with recombinant IGF1 led to a significant increase in in
vitro cell migration capacities for both K7M2 and U2OS
cells (+ 81% and + 53%, respectively; p < 0.05; Fig. 7a-b). On
the other hand, the addition of a blocking/neutralizing
anti-IGF1 antibody led to an inhibition of cell migration
capacities (− 52% and − 43%, respectively; p < 0.05).
K7M2 and U2OS osteosarcoma cells were then tested
for anchorage-independent cell aggregation (Fig. 7c-e).
CYR61-silenced cells were less able to interact with one
another and form smaller aggregates than control cells.
The silencing of CYR61 thus led to a decrease in the
surface of aggregates (− 51%, p < 0.05), and increase in
the aggregate number (+ 76%, p < 0.05). Conversely,
CYR61-overexpressing cells can more easily adhere to
each other and form larger cell aggregations (2.3-fold
and + 46%, respectively, p < 0.05), and less numerous ag-
gregates (− 53%, p < 0.05). Supplementation of culture
medium with a blocking/neutralizing anti-IGF1 antibody
normalized the surface and number of aggregates
formed from CYR61-overexpressing cells.
These results suggest that CYR61 controls osteosar-
coma cell-cell interactions and cell motility through an
IGF-dependent process.
CYR61 level influences the expression of EMT markers
and cell motility through a JNK-dependent pathway
As we previously demonstrated that osteosarcoma cell
motility and invasiveness are dependent on JNK pathway
[23], CYR61-modified cells were tested for in vitro cell
migration in the presence of the JNK inhibitor
SP600125. Concentrations as high as 10–15 μM were re-
quired to significantly reduce JNK phosphorylation levels
(Additional file 4: Figure S4). Those high concentrations
led to a detectable reduction of wound healing capacities
for K7M2 and U2OS control cells (Fig. 8a-b). In con-
trast, low concentrations of the JNK inhibitor SP600125
allowed significantly affecting CYR61-overexpressing K7
M2 and U2OS cells. Supplementation with 10–15 μM
JNK inhibitor led to a complete abrogation of the stimu-
latory effect of CYR61 on wound healing.
The gene expression level of EMT markers was assessed
by real-time RT-qPCR. Medium supplementation with JNK
inhibitor SP600125 (15 μM) led to reduced expression
levels of mesenchymal-related markers (Snail-1, Snail-2/
Slug, Twist1, N-cadherin, Vimentin) and enhanced
expression levels of epithelial-related markers (E-cadherin,
Occludin, Desmoplakin) in CYR61-overexpressing cells
(Fig. 8c). On the other hand, transient transfection of
CYR61-silenced cells to express a constitutively active form
of MKK7 coupled to JNK led to an enhanced expression of
mesenchymal-related markers, and to a reduction in gene
expression levels of epithelial-related markers (Fig. 8d).
Altogether, these results indicate that CYR61 modu-
lates EMT markers expression and cell motility at least
in part through modulation of JNK activity.
Discussion
Our results provide evidence that in osteosarcoma cells
CYR61 plays a key role in the modulation of expression
of some phenotypic markers leading to a process similar
to the epithelial-to-mesenchymal transition (EMT) ob-
served in tumors of epithelial origin. This resulted in the
promotion of cell motility and invasiveness, leading to
the enhancement of metastatic dissemination of the pri-
mary tumor. Our results also demonstrate that a major
effector pathway involved was the modulation of IGF1
and its receptor IGF1Rβ by CYR61. The silencing of
CYR61 or the blockade of IGF1/IGF1Rβ pathway signifi-
cantly reduced the pro-metastatic activity of osteosar-
coma cells, as demonstrated in vitro or in preclinical
models.
The involvement of a mesenchymal transition process
in the onset and progression of sarcomas of different
origins has been very recently discussed in the review of
Kahlert and colleagues [24], suggesting EMT and
mesenchymal-to-epithelial transition (MET)-related
processes in non-epithelial tumors. Osteosarcoma cells
have been reported to undergo an “EMT-like” process
that associate with their metastatic ability [17–20]. We
found more appropriate to use the term of “EMT-like”
to describe the phenotype observed in our models. Our
data indeed demonstrate that CYR61 overexpression led
to (i) a reduction in expression level of molecular markers
considered as epithelial such as E-cadherin, occludin,





Fig. 7 (See legend on next page.)
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zonula occludens-1 or desmoplakin, leading to decreased
cell aggregation; (ii) upregulation of mesenchymal molecu-
lar markers such as N-cadherin, vimentin, or mucin-1; (iii)
cytoplasmic elongation and acquisition of a more fibroblas-
tic shape; and,, (iv) increased migratory and invasive poten-
tial, and also (v) enhanced resistance to basal cell death and
chemotherapy compounds, as we previously demonstrated
[11, 12]. Conversely, silencing CYR61 in osteosarcoma cells
led to the reverse process, namely MET where cells
adopted a more cuboid shape, tended to aggregate because
of higher level of cell-cell adhesion proteins (shift from
N-cadherin to E-cadherin), and secreted less MMPs.
Altogether, our results clearly point to CYR61 as a critical
player in osteosarcoma behavior by affecting both tumor
cells (cytoskeleton reorganization, cell-cell contacts…) and
microenvironment of primary tumor (extracellular matrix
synthesis, proteases expression, neo-angiogenesis).
Our results support the proposal of the induction of
EMT-like in osteosarcoma cells when CYR61 expression
rises. Those variations in general hallmarks of EMT were
also detected in vivo in a preclinical murine model of
tumors derived from genetically modified osteosarcoma
cells expressing various controlled levels of CYR61. We
further confirmed a positive correlation between tumor
grade, CYR61, and N-cadherin expression levels in tissue
samples originating from patients suffering of localized
and metastatic osteosarcoma. Our results are consistent
with the reported induction of EMT under overexpression
of CYR61 in laryngeal squamous cell carcinoma, pancre-
atic cancer cell lines, gastric cancer, osteosarcoma or
chondrosarcoma [25–29]. EMT being a key process for
tumor cells to disseminate to distant organs, our results
provide further evidence that CYR61 is a key inducer of
osteosarcoma metastatic spreading.
From a mechanistic point of view, members of CCN fam-
ily can interfere with signal transduction of growth factors
such as FGF, PDGF, TGFβ or BMPs [30, 31]. Recently,
insulin-like growth factor 2 receptor (IGF2R) has been
suggested as CTGF-interacting protein in fibroblasts [32].
With regard to CYR61, integrin receptors and
heparin-sulfate proteoglycans (HSPGs) binding sites have
been largely documented [30]. Among its four conserved
structural domains, CYR61 includes an insulin-like growth
factor-binding protein (IGFBP) homology domain a reason
why it was formerly called IGFBP10. IGFs are the most
abundant growth factors produced by osteoblasts [33] and
stored in bone matrix. IGF increases bone formation by
regulating the proliferation, differentiation, and apoptosis of
osteoblasts by binding IGF receptor type 1 (IGF1Rβ). This
IGF system plays an important role in the development of
osteosarcoma [34]. In this study, we showed that IGF1Rβ
expression levels increases with tumor aggressiveness status
in our preclinical murine model and in human tumor
samples. This is in accordance with the correlation
mentioned between elevated IGF1R mRNA expression
and distant metastasis occurrence in human osteosarcoma
tumor [35, 36].
We also demonstrated that CYR61 levels influence IGF1
and IGF1Rβ expression (at a transcriptional level), result-
ing in the modulation of some IGF1Rβ downstream sig-
naling such as JNK. Activating JNK-MAPKs signaling
pathway promotes EMT in tumor cells (reviewed in [37]).
Our results conformed well to that since the inhibition or
activation of JNK activity interferes with the relative ex-
pression levels of epithelial and mesenchymal markers in
osteosarcoma cells. We also previously demonstrated that,
by controlling MMP2/MMP9 expression and activity, the
JNK/c-Jun signaling pathway plays a key role in osteosar-
coma potential for metastasis [23, 38]. In the present
study, we finally established that CYR61 influences the
expression of EMT markers and cell motility through a
JNK-dependent pathway.
Much effort has been devoted to develop anticancer
agents that block IGF/IGFR signaling pathway. In vitro
and preclinical assays evaluating inhibitors or antagonists
of IGF receptors or ligands have reported positive effects
in regulating tumorigenic and metastatic properties of
osteosarcoma cells [39–43]. Those promising results
encouraged the assessment of targeting IGF pathway in
patients. Phase-I and phase-II clinical trials evaluating
IGF-1R antibodies as therapy for osteosarcoma patients
have returned mixed results. Despite the very small
percentage of osteosarcoma patients included in those
trials, and thus delicate interpretation of the results, sev-
eral stable disease and partial/complete response were
reported [44–46]. Some clinical trials focusing on mono-
clonal anti-IGF1R in patients with relapsed and/or recur-
rent osteosarcoma are ongoing. Revealing the upstream
inducer function of CYR61, alias IGFBP10, our results
firstly reinforce the importance of the IGF pathway into
(See figure on previous page.)
Fig. 7 CYR61 influences cell motility and cell-cell interaction through the IGF1/IGF1Rβ pathway. a Migration of K7M2 and U2OS cell lines
incubated in the presence or absence of recombinant IGF1 or neutralizing anti-IGF1 antibody, as assessed by wound healing assays. Pictures were
taken at time 0 and 18 hrs after the wound. b Quantitative evaluation of the wound healing. Results are expressed as mean ± standard deviation.
a: p < 0.05 vs. control cells. c Cell aggregation assay of K7M2 and U2OS cell lines cultured in the presence or absence of neutralizing anti-IGF1
antibody. d Quantitative evaluation of the relative aggregate surface. Results are expressed as mean ± standard deviation. a: p < 0.05 vs. control
cells; b: p < 0.05 vs. untreated. e Quantitative evaluation of the relative number of particles. Results are expressed as mean ± standard deviation.
a: p < 0.05 vs. control cells; b: p < 0.05 vs. untreated




Fig. 8 CYR61 influences cell motility and the expression of EMT markers through a JNK-dependent pathway. a Migration of K7 M2 and U2OS cell
lines incubated in the presence or absence of the JNK inhibitor SP600125 (15 µM), as assessed by wound healing assays. Pictures were taken at
time 0 and 18 h after the wound. b Quantitative evaluation of the wound healing. Results are expressed as mean ± standard deviation. a: p < 0.05
vs. control cells; b: p < 0.05 vs. untreated. c Expression pattern of a panel of mesenchymal and epithelial markers in K7M2 cell lines cultured in
the presence or absence of the JNK inhibitor SP600125, as assessed by RT-qPCR. The relative mRNA levels were calculated using the 2–ΔΔCT
method and expressed as Log2 of fold change (mean ± standard deviation). a: p < 0.05 vs. control cells; b: p < 0.05 vs. untreated. d Expression
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osteosarcoma pathogenesis, and also open up new thera-
peutic opportunities for aggressive osteosarcoma or pri-
mary tumors exhibiting a high metastatic risk.
Receptors with tyrosine kinase activity (RTKs) are
reported substantially involved in development and
progression of osteosarcoma [47]. We indeed previ-
ously reported that metastatic and recurrent osteosar-
coma tumors expressed higher EGFR and PDGFRα
levels than localized tumors [22]. The present study
provides evidence of a positive correlation between
IGF1Rβ expression level and aggressive tumor devel-
opment. Surprisingly, among the tested RTKs, only
IGF1Rβ level variations correlated with that of
CYR61, reinforcing the key role of IGF pathway in
metastatic osteosarcoma. This also confirms the rele-
vance for developing strategy to block these
CYR61-dependent pro-metastatic signals.
As CYR61 need partners to transduce its pro-meta-
static signal, the involvement of major signaling effec-
tors should not be overlooked. As an example, the
YAP1 (Yes-associated protein)/TAZ (transcriptional
coactivator with PDZ-binding motif ) are reported to
play an important role in tumor initiation and cancer
progression, and may be proposed as prognostic bio-
marker in gastric, breast, ovarian, renal and prostate
cancers (reviewed in [48]). The up-regulation of YAP
in osteosarcoma tissue has been reported [49, 50].
Cyr61 is one of the transcriptional targets and down-
stream effectors of YAP/TAZ [51]. It could be specu-
late that a cooperation or relationship between YAP/
TAZ pathway and CYR61 may play a key role in
osteosarcoma progression. In a similar way, interfer-
ence with Wnt/β catenin signaling pathways may be
considered as CYR61 is a downstream effector of
these substantial contributors to osteosarcoma
tumorigenesis [52, 53].
Conclusions
Our current results provide evidence that CYR61
plays a crucial role in the complex processes of pri-
mary tumor dissemination. CYR61 controls the IGF/
IGFR levels and triggers an EMT-like process. This
allows tumor cells to acquire morphological changes,
to increase invasiveness to the surrounding stroma.
Combined to our previous studies, reporting the es-
sential promoting role of CYR61 in primary tumor
vascularization, this study suggests CYR61 as a novel
candidate biomarker of osteosarcoma associated with
aggressiveness and with metastasis. Targeting of this
molecule could additionally represent a valuable
therapeutic strategy in osteosarcoma to prevent can-
cer progression and metastatic disease. Our data also
strongly support the need to evaluate IGF/IGFR path-
way under CYR61 context in osteosarcoma patients.
Methods
Reagents and antibodies
Recombinant CYR61 and SP600125 were purchased
from Sigma-Aldrich (Lyon, France), recombinant IGF-1
was purchased from R&D Systems (Lille, France).
Neutralizing anti-IGF1 antibody was purchased from
R&D Systems. Rabbit polyclonal anti-CYR61 and anti-
pIGF1Rβ were purchased from Abcam (Cambridge, UK),
anti-Actin was purchased from Sigma Aldrich and
anti-IGF1Rβ, anti-pGSK3β, anti-pJNK, anti-JNK were pur-
chased from Cell Signaling Technology (Saint Quentin en
Yvelines, France). Mouse monoclonal anti-E-cadherin was
purchased from Santa Cruz Biotechnologies (Santa Cruz,
CA, USA), anti- GSK3β was purchased from Cell Signaling
Technology, and anti-IGF1 was purchased from R&D
Systems.
Cell lines and culture
Murine K7M2 and human U2OS osteosarcoma cells
(American Type Culture Collection, Rockville, MD,
USA) were transduced with lentiviral vectors encoding
either the full-length coding sequence or specific shRNA
sequences as previously described [12] to stably increase
or reduce CYR61 expression, respectively. All cell lines
were cultured in high glucose Dulbecco’s Modified Ea-
gles Medium (DMEM; Invitrogen Corporation, Paisley,
Scotland) supplemented with 10% heat inactivated fetal
calf serum at 37 °C in an atmosphere of > 95% humidity
and 5% CO2. Culture media were changed three times a
week and regularly tested to ensure absence of
mycoplasma.
Spheroid formation
Osteo-spheroids were generated by seeding 5000 cells/
well in poly-Hema coated 96-well round-bottomed
plates. Medium was supplemented with Matrigel (4 mg/
ml) at day 2 to allow invasion. Images were captured
using EVOS Cell Imaging System (Thermo Fisher
Scientific).
RNA extraction
Total RNAs were isolated using TRIzol Reagent
(Thermo Fisher Scientific, Courtabœuf, France), accord-
ing to the manufacturer’s protocol, suspended in H2O
supplemented with RNAsecure reagent (Thermo Fisher
pattern of a panel of mesenchymal and epithelial markers in K7M2 cell lines transfected with a MKK7-JNK expressing vector or the corresponding
empty vector, as assessed by RT-qPCR. The relative mRNA levels were calculated using the 2–ΔΔCT method and expressed as Log2 of fold change
(mean ± standard deviation). a: p < 0.05 vs. control cells; b: p < 0.05 vs. untreated
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Scientific) and stored at − 80 °C. RNA Integrity was
checked using an Agilent 2100 BioAnalyzer to select
samples exhibiting RNA Integrity Number > 8.
Real-time RT-PCR
Total RNA (3 μg) were denatured for 10 min at 70 °C
then reverse transcribed at 37 °C for 90 min using 300 U
MMLV reverse transcriptase, 15 μg random hexamers, 1
mM deoxynucleoside triphosphate (dNTP) in 30 μl total
volume. Real-time quantitative Polymerase Chain Reactions
(qPCR) were performed on ViiA7 apparatus (Thermo
Fisher Scientific) using SYBrGreen Master kit (Thermo
Fisher Scientific) supplemented with 0.5 μM of specific
primers (Additional file 5: Table S1 and Additional file 6:
Table S2). Thermal conditions were: 15min at 95 °C for ac-
tivation then 50 cycles of denaturation at 95 °C for 20 s, 58 °
C annealing for 15 s and 72 °C extension for 15 s. Melting
curve analysis was included to assure that only one PCR
product was formed. The relative amounts of RNA were
calculated by the 2-ΔΔCt method.
Enzyme-linked immunosorbent assays (ELISA)
Conditioned media were collected after 48 h of culture
under serum-free conditions and cleared from cell debris
by centrifugation. ELISAs were performed immediately
for IGF-1, in accordance with the manufacturers’ recom-
mendations (R&D Systems).
In vitro wound healing
Cells were seeded in each chamber of the Culture-Insert
(Ibidi; Martinsried, Germany) and incubated for 24 h in
medium supplemented with 2.5% FCS. Confluent cell
monolayers were carefully washed once with phosphate
buffered saline (PBS), cultured for 18 h, fixed in 75%
ethanol and stained with crystal violet (0.05% in etha-
nol). Recovery of the denuded area was computerized
using EVOS digital microscope (Delta Microscopies,
Ayguesvives, France). Lesion area surface at time zero
was used as matrix for cell number evaluation in other
lesion areas. Six replicates were used for each condition
and experiments were repeated three times.
Cell aggregation assay
Cells were seeded (105 cells/cm2) in bacteriological grade
culture plates. After 24 h, plates were placed on a gyr-
atory shaker for 60 min at 37 °C to allow cell aggrega-
tion. Single cells and cell clusters were counted and cell
aggregation was evaluated using ImageJ software. Experi-
ments were repeated three times with 3–4 replicates for
each condition.
Cell adhesion assay
Wells were coated or not with type I collagen (5 μg/mL),
laminin (0.5 μg/mL) or fibronectin (2 μg/mL) by
overnight incubation at 37 °C in 5% CO2. The coated
wells were washed twice with PBS followed immediately
by cell seeding (105 cells/cm2). After 30 min, the super-
natant was removed, cell layers were carefully washed
once with PBS and fixed with 4% paraformaldehyde for
20 min at + 4 °C. Wells were stained with crystal violet
(0.05% in ethanol) before computerization using EVOS
digital microscope.
Western blot
Cell lysates were prepared as previously described [54].
Proteins (30 μg) were resolved on 12% SDS-PAGE and
electro-transferred onto PVDF membranes. Those mem-
branes were incubated for 2 h in blocking buffer (Sigma
Aldrich), then overnight at 4 °C with specific primary
antibodies (0.5 μg/mL). Membranes were washed twice
with [50mM Tris/HCl pH 7.4, 150mM NaCl, 0.1% (v/v)
Tween-20] (TBST) and incubated for 2 h with appropriate
HRP-conjugated secondary antibody (1/20,000). After
final washes, the signals were visualized with enhanced
chemiluminescence western blotting detection reagent
(Thermo Fisher Scientific) on the ChemiDoc XRS+ appar-
atus (BioRad Laboratories, Marnes-la-Coquette, France)
and quantified using the ImageJ software.
Reporter assay
Cells were seeded (4000 cells/cm2) in 6-well plates and
transiently co-transfected the day after with 0.2 μg/well
pOLUC-IGF1R [55] and 0.2 ng/well of pCH110
(Addgene, Cambridge, MA, USA) using Lipofecta-
min2000 reagent (Thermo Fisher Scientific) according to
manufacturer’s recommendations. Cells were cultured
for further 36 h. Transcriptional activity was evaluated
using a Luciferase Reporter Assay System according to
the manufacturer’s protocol (Promega) and corrected to
beta-galactosidase activity evaluated using β-Gal reporter
gene assay (Roche, Meylan, France).
Cell-line-derived xenograft (CDX) models
In vivo assay was performed as previously described
[11, 12]. Briefly, after acclimatization for 7 days, 5-week
old BALB/c mice (Charles River, Arbresle, France) were
intramuscularly injected with K7M2 osteosarcoma cells
(106 cells/15 μl PBS) in both thigh muscles under isoflur-
ane/air inhalational anaesthesia. At day 28 after cell injec-
tion, mice were killed by CO2 asphyxiation. Muscle
infiltrated with tumor tissues and lungs were collected,
formalin-fixed then embedded in paraffin.
Osteosarcoma tissue microarray (TMA)
An osteosarcoma tissue microarray composed of 233 tis-
sue cores included in paraffin (205 tumor samples and
28 normal bone samples) was used for an IHC study.
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The characteristics of the patients are summarized in
Additional file 1: Figure S1A-E.
Hematoxylin and eosin (H&E) staining and
immunohistochemistry
The deparaffinization of formalin-fixed paraffin-embed
ded tissue sections (5 μm) was performed in xylene be-
fore the dehydration through a graded alcohol series.
Lung and tumor tissue samples were stained with
hematoxylin and eosin (H&E) for histological analyses.
Tumor tissue sections were micro-waved in citrate buffer
(pH 6.0) for epitopes unmasking then incubated for 5min
in 3% H2O2 for endogenous peroxidase quenching. The
sections were incubated with anti-CYR61 (5 μg/mL),
anti-N-Cadherin (20 μg/mL, Abcam), anti-E-Cadherin
(4 μg/mL) or anti-IGF1Rβ (2 μg/mL) antibodies overnight
at 4 °C, in humidified atmosphere. Primary antibodies
were detected using Vectastain Elite ABC system (Vector
Laboratories Ltd., Peterborough, UK). Negative control
sections were incubated with antibody diluent, without
primary antibody, followed by incubation with secondary
antibody. Signal intensity was quantified on 15–18 fields
located outside of the necrotic areas and without the
remaining muscular fibers using ImageJ 1.51p. The TMA
slides were processed as above. Signal intensity was esti-
mated by two observers without prior information about
TMA spots and thereafter related to clinical information.
Statistical analysis
Comparisons between data were performed using the
two-factor analysis of variance using the statistical pack-
age ANOVA. Preclinical data was analyzed using
non-parametric Mann-Whitney test. A minimal level of
P < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Characteristics of patients whose tumor
samples are included in tissue micro-array (TMA). A total of 231 core sam-
ples were collected from 37 patients with osteosarcoma (205 tumor sam-
ples), and 28 normal bone samples. (A) Frequency distribution of patients
by age (years) at diagnosis. (B) Histologic subtypes (%). (C) Kaplan-Meier
survival curve for overall survival of Male and Female. (D) Kaplan-Meier
survival curve for overall survival of patients with localized of metastatic
tumor at diagnosis. (E) Kaplan-Meier survival curve for overall survival of
patients experiencing relapse or not. (PPTX 93 kb)
Additional file 2: Figure S2. CYR61 controls osteosarcoma cell
phenotype in vitro. (A) Morphology of K7 M2 and U2OS osteosarcoma
control, CYR61 silenced and CYR61 overexpressing cells, grown in
medium supplemented with 10% Fetal Calf Serum. (B) Correlation
between the relative maximal cell length of K7 M2 and U2OS cells.
Results are expressed as mean ± standard deviation (n > 2000 cells/field;
at least 8 field/condition; experiments repeated twice). (C) Brightfield
imaging of osteo- spheroids. (D) Quantitative evaluation of the relative
aggregate surface. Results are expressed as mean ± standard deviation (n
= 6). a: p < 0.05 vs. control cells. (E) Relative K7 M2 cell number adherent
to the indicated surface, after 30 min incubation. Results are expressed as
Log2 of fold change (mean ± standard deviation). a: p < 0.05 vs. control
cells. (PPTX 3906 kb)
Additional file 3: Figure S3. CYR61 expression level does not correlate
with those of EGFR or PDGFR. Box plot of IHC staining scores for EGFR
(A), and PDGFR (B). Spearman correlation between EGFR (C) and PDGFR
(D) expression levels and CYR61 expression levels in human samples.
Spearman correlation between EGFR (E) and PDGFR (F) expression levels
and N-cadherin expression levels in human samples. (PPTX 201 kb)
Additional file 4: Figure S4. SP600125 inhibitory effect on JNK
phosphorylation. Expression pattern of phospho-JNK and phospho-
ERK1/2 as well as corresponding total protein in K7 M2 and U2OS cell
lines, cultured ON in the presence of increasing concentration of
SP600125, as assessed by Western blot. Actin was used as loading
control. (PPTX 2635 kb)
Additional file 5: Table S1. Primer sequences for real time quantitative
PCR (mouse). (DOCX 16 kb)
Additional file 6: Table S2. Primer sequences for real time quantitative
PCR (human). (DOCX 16 kb)
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